HIGHLIGHTS
- who: Lucia Leccisotti from the Centro Malattie Endocrine E Metaboliche, Dipartimento Di Scienze have published the research: Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report, in the Journal: (JOURNAL)
- what: The authors provide new insight into SGLT-2i CV benefits as the data show that patients on SGLT-2i are more resistant to the detrimental effects of obstructive coronary atherosclerosis due to increased MFR probably caused by an improvement in coronary microvascular dysfunction. The aim of this study was to evaluate whether SGLT-2i treatment with . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.